The Fermi Gamma-ray Burst Monitor: Results from the first two years

In the first two years since the launch of the Fermi Observatory, the Gamma-ray Burst Monitor (GBM) has detected over 500 Gamma-Ray Bursts (GRBs), of which 18 were confidently detected by the Large Area Telescope (LAT) above 100 MeV. Besides GRBs, GBM has triggered on other transient sources, such as Soft Gamma Repeaters (SGRs), Terrestrial Gamma-ray Flashes (TGFs) and solar flares. Here we present the science highlights of the GBM observations.Comment: 4 pages, 1 figure, Proceedings of the 8th Workshop on Science with the New Generation of High Energy Gamma-ray Experiments (SciNeGHE 2010), Nuovo Cimento C, in pres

Higher-Order Recombination Processes in Argon Ions Observed via X-ray Emission in an EBIT

Funding Information: W.B.-N. acknowledges the GET_INvolved Programme at FAIR/GSI and the JIPhD program through contract POWR.03.05.00-00-Z309/17-00. F.G. acknowledges support from FCT (Portugal) through contract UI/BD/151000/2021. Publisher Copyright: © 2022 by the authors.In electron–ion collisions, recombination processes play a very important role. Recently, multielectron recombination processes have been highly investigated, as they carry information about electron–electron interaction. Among them, the most basic process is dielectronic recombination (DR). The research presented here was conducted using an EBIT at Jagiellonian University. Using X-ray spectroscopy, we conducted research into K-LL, K-LM, K-LN, K-LO and K-MM resonances. The aim of this study was to investigate the contribution of the intershell higher-order recombination processes in collected spectra. A good resolution for the K-LL DR spectrum made it possible to distinguish structures for He- up to C-like Ar ions.publishersversionpublishe

Definition, diagnosis and treatment of oligometastatic oesophagogastric cancer: A Delphi consensus study in Europe

Background: Local treatment improves the outcomes for oligometastatic disease (OMD, i.e. an intermediate state between locoregional and widespread disseminated disease). However, consensus about the definition, diagnosis and treatment of oligometastatic oesophagogastric cancer is lacking. The aim of this study was to develop a multidisciplinary European consensus statement on the definition, diagnosis and treatment of oligometastatic oesophagogastric cancer. / Methods: In total, 65 specialists in the multidisciplinary treatment for oesophagogastric cancer from 49 expert centres across 16 European countries were requested to participate in this Delphi study. The consensus finding process consisted of a starting meeting, 2 online Delphi questionnaire rounds and an online consensus meeting. Input for Delphi questionnaires consisted of (1) a systematic review on definitions of oligometastatic oesophagogastric cancer and (2) a discussion of real-life clinical cases by multidisciplinary teams. Experts were asked to score each statement on a 5-point Likert scale. The agreement was scored to be either absent/poor (2 years, either upfront local treatment or systemic treatment followed by restaging was considered as treatment (fair agreement). / Conclusion: The OMEC project has resulted in a multidisciplinary European consensus statement for the definition, diagnosis and treatment of oligometastatic oesophagogastric adenocarcinoma and squamous cell cancer. This can be used to standardise inclusion criteria for future clinical trials

A Latent Growth Curve Analysis

Funding Information: This work was supported by the European Union’s Horizon 2020 Research and Innovation Programme under Grant Agreement No. 777167. Dr. Lauren Kelada is supported by the Golda Meir Post-Doctoral Fellowship Fund. Publisher Copyright: © 2023 by the authors.The current study aimed to track the trajectory of quality of life (QoL) among subgroups of women with breast cancer in the first 12 months post-diagnosis. We also aimed to assess the number and portion of women classified into each distinct trajectory and the sociodemographic, clinical, and psychosocial factors associated with these trajectories. The international sample included 699 participants who were recruited soon after being diagnosed with breast cancer as part of the BOUNCE Project. QoL was assessed at baseline and after 3, 6, 9, and 12 months, and we used Latent Class Growth Analysis to identify trajectory subgroups. Sociodemographic, clinical, and psychosocial factors at baseline were used to predict latent class membership. Four distinct QoL trajectories were identified in the first 12 months after a breast cancer diagnosis: medium and stable (26% of participants); medium and improving (47%); high and improving (18%); and low and stable (9%). Thus, most women experienced improvements in QoL during the first year post-diagnosis. However, approximately one-third of women experienced consistently low-to-medium QoL. Cancer stage was the only variable which was related to the QoL trajectory in the multivariate analysis. Early interventions which specifically target women who are at risk of ongoing low QoL are needed.publishersversionpublishe

Development of NEW, towards the first physics results of NEXT

The NEXT ßß0¿ experiment will use a high-pressure gas electroluminescent TPC to search for the decay of Xe- 136. The development, construction and installation of NEXT-WHITE (NEW), the first radio-pure version of NEXT, will take place this year at Laboratorio Subterra ´neo de Canfranc. NEW will run initially using 10 kg of natural xenon during which time NEXT technology will be validated and the topological reconstruction algorithms refined. Moreover, the background model will be benchmarked using data. A second run will use enriched xenon and will make a first measurement of the two neutrino channel (ßß2¿) by NEXT. This poster will present the various technical aspects of the detector detailing the radio-pure solutions for a low backgorund experiment and the low noise, high resolution measurement of both energy and position

déjà vu?: planning for the Covid-19 third wave and planning for the winter 2021–22

publishersversionpublishe

The arabin pessary to prevent preterm birth in women with a twin pregnancy and a short cervix : The STOPPIT 2 RCT

Funding Information: The research reported in this issue of the journal was funded by the HTA programme as project number 13/04/22. The contractual start date was in November 2014. The draft report began editorial review in September 2020 and was accepted for publication in February 2021. The authors have been wholly responsible for all data collection, analysis and interpretation, and for writing up their work. The HTA editors and publisher have tried to ensure the accuracy of the authors’ report and would like to thank the reviewers for their constructive comments on the draft document. However, they do not accept liability for damages or losses arising from material published in this report. Declared competing interests of authors: Jane E Norman has received grants from government and charitable bodies for research into understanding the mechanism of term and preterm labour and understanding treatments. Within the last 3 years, Jane E Norman has acted on a Data Safety and Monitoring Board for a study involving a preterm birth therapeutic agent for GlaxoSmithKline plc (GlaxoSmithKline plc, Brentford, UK) and has provided consultancy for a small pharmaceutical company (Dilafor AB, Solna, Sweden) on drugs to alter labour progress. She was on the Health Technology Assessment (HTA) Maternal Neonatal and Child Health Panel (2013–18) and she was a member of the National Institute for Health Research (NIHR) HTA and Efficacy and Mechanism Evaluation (EME) Editorial Board (2012–14). John Norrie reports grants from the University of Edinburgh (Edinburgh, UK) during the conduct of the study, and declares that he is or has been a member of the following: HTA Commissioning Sub-Board (EOI) (2012–16), NIHR CTU Standing Advisory Committee (2017–present), NIHR HTA and EME Editorial Board (2014–19), Pre-Exposure Prophylaxis Impact Review Panel (2017–present), EME Strategy Advisory Committee (2019–present), EME – Funding Committee Members (2019–present), EME Funding Committee Sub-Group Remit & Comp Check (2019–present), HTA General Committee (2016–19), HTA Funding Committee Policy Group (formerly Clinical Studies Group) (2016–19), HTA Commissioning Committee (2010–16) and was a member of the HTA and EME Editorial Board between 2014 and 2019. Sarah Cunningham-Burley reports personal fees and other from the Wellcome Trust (London, UK), other from the University of Copenhagen (Copenhagen, Denmark), other funding from NIHR Global Health Research, personal fees from the French National Cancer Institute (Paris, France) and personal fees from the Health Research Board (Dublin, Ireland), outside the submitted work. Andrew Shennan is a member of the NIHR HTA Commissioning Committee (2018–22). Stephen C Robson was a member of the NIHR EME Funding Committee (2012–15). Steven Thornton is a trustee of a number of charities, including those that fund related research. He reports personal fees from GlaxoSmithKline plc, during the conduct of the study and outside the submitted work, and personal fees from Johnson & Johnson (Johnson & Johnson, Brunswick, NJ, USA) for consulting services. He holds positions in the Royal College of Obstetricians and Gynaecologists (London, UK) and other organisations. He was a member of the NIHR EME Strategy Advisory Committee (2018–19), EME – Funding Committee Members (2015–19), EME Funding Committee Sub-Group Remit & Comp Check (2018–19) and the Medical Research Council Multimorbidity Board (2020). Neil Marlow reports personal fees from Shire-Takeda (London, UK), Novartis Pharmaceuticals UK Ltd (London, UK) and GlaxoSmithKlein plc, outside the submitted work. Sarah J Stock declares that she is a member of the NIHR HTA General Committee (2016–22). In addition, Sarah J Stock received other research funding from the NIHR (14/32/01 QUIDS), Wellcome Trust (209560/Z/17/Z) and Chief Scientist Office (Edinburgh, UK), during the course of the study. Philip R Bennett reports personal fees and membership of a scientific panel from ObsEva (Plan-les-Ouates, Switzerland), outside the submitted work. In addition, Philip R Bennett has a patent PCT/GB1997/000529 WO1997031631 A1 ‘COX-2 selective inhibitors for managing labour and uterine contractions’ issued, a patent PCT/GB2004/001380 WO2005053705 A1 ‘Use of a cyclopentenone prostaglandin for delaying the onset and/or preventing the continuation of labour’ (priority date 2 December 2003) issued, a patent PCT/GB2016/050618 ‘Circulating miRNAs predictive of cervical shortening and preterm birth’ (pending UK filing 6 March 2015/full international filing completed 7 March 2016) issued, a patent PCT/GB2016/ 050621 ‘Rapid evaporative ionisation mass spectroscopy (REIMS) and desorbtion electrospray ionisation mass spectroscopy (DESI-MS) analysis of swabs and biopsy samples’ (pending UK filing 6 March 2015/full international filing completed 7 March 2016) pending, a patent PCT/GB2019 ‘Desorbtion electrospray ionisation mass spectroscopy (DESI-MS) analysis of swabs to predict vaginal microbiota’ (pending UK filing March 2019) pending, and a patent PCT/GB2019/ ‘Circulating miRNAs predictive of IUGR’ (pending UK filing March 2019) pending.Publisher PD

Association between periconceptional weight loss and maternal and neonatal outcomes in obese infertile women

Funding: The study was supported by a grant from ZonMw (www.zonmw.nl), the Dutch Organisation for Health Research and Development (50-50110-96-518). AH was project leader and received the funding. ZonMw had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. Acknowledgments: We would like to thank the women who participated in this study. We thank all participating hospitals and their staff for their contribution to this study, and the lifestyle coaches and research nurses and research midwives for their hard work and dedication. We thank Ms. A. Bolster for her role as senior training intervention coach. We thank the members of the safety monitoring board (Dr G.E. Mantel, Dr K Fleischer, Dr W. Dondorp, Prof. M.E.A. Spaanderman) who reviewed the major complications, and office members of the Dutch ConsortiumPeer reviewedPublisher PD

Effect of a lifestyle intervention in obese infertile women on cardiometabolic health and quality of life : A randomized controlled trial

This study has been conducted with the support of a grant (50-50110-96-518) from the Netherlands Organization for Health Research and Development and the Dutch Heart Foundation grant: 2013T085. Ben Willem J. Mol is supported by a NHMRC Practitioner Fellowship (GNT1082548).Peer reviewedPublisher PD

A Profile of Third-Grade Proficiency in Erie County

Produced by the United Way of Buffalo and Erie County, this report details information about why it is important for third graders in Erie County to be proficient in reading and math. Children below grade-level proficiency in third grade are much less likely to graduate from high school.Without mastering early reading and math skills, a child will fall further and further behind their peers. Without a high school degree, our children will face a future in which they are less likely to be able to support themselves through employment, and are more likely to live in poverty